Therefore, our data suggest that a minority of VSCC patients would benefit from a therapy with monoclonal antibodies against VEGF (bevacizumab), which currently represents a therapeutic option for recurrent/metastatic cervical cancer approved by the FDA [62,63]. Here, VEGFA is linked to cervical cancer.